Tailored strategy for AML patients receiving allogeneic peripheral blood stem cell transplantation.
Considering the heterogeneity of acute myelogenous leukemia (AML), along with the pros and cons of allogeneic peripheral blood stem cell transplantation (PBSCT), a tailored strategy is needed to minimize the transplant-related mortality and maximize the transplant outcomes in AML patients exhibiting certain factors that have an impact on the post-transplant quality of life and outcomes. The factors that need to be considered when tailoring a strategy in an allogeneic PBSCT setting include the recipient's performance status and co-morbid disease include AML risk stratification, disease status, expected severity of graft-versus-host disease, and the necessity of a graft-versus-leukemia effect. Accordingly, this review article describes a possible tailoring strategy for AML patients receiving allogeneic PBSCT based on certain factors influencing the transplant outcome.
Sohn
Sang Kyun
SK
Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea. ksohn@knu.ac.kr
Kim
Jong Gwang
JG
Kim
Dong Hwan
DH
D000328:Adult; D000368:Aged; D020544:Graft vs Leukemia Effect; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D012306:Risk; D013234:Stem Cells / Q000166:cytology*; D014184:Transplantation, Homologous; D016896:Treatment Outcome